{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:32:08Z","timestamp":1793381528215,"version":"4.5.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme-Chibret"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lilly France"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vifor Fresenius"},{"name":"Sano -Genzyme"},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme-Chibret","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sano -Genzyme"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French government"},{"name":"Daichii"},{"name":"Sano - Genzyme"},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chronic inflammation is associated with cardiovascular disease in the general population, but data on patients with chronic kidney disease (CKD) are limited. We sought to assess whether systemic low-grade inflammation is independently associated with cardiovascular events in CKD patients not yet on kidney replacement therapy, with or without a history of atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The French CKD\u2013Renal Epidemiology and Information Network is a prospective cohort study of adults with CKD stages 2\u20135, conducted in 40 French nephrology outpatient facilities. Baseline high-sensitivity plasma C-reactive protein (hs-CRP) was centrally measured using an immunoturbidimetric method. Systemic low-grade inflammation was defined as hs-CRP \u22652\u2005mg\/L. Cox proportional hazards models estimated cause-specific hazard ratios (HR) and 95% confidence intervals (CI) for major adverse cardiovascular events (MACE; composite of stroke, myocardial infarction, or cardiovascular death) or hospitalization for heart failure (HHF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 2078 patients: 67% men, mean (SD) age 67(13) years, mean estimated glomerular filtration rate 36(12) mL\/min\/1.73\u2005m2, 38% with history of ASCVD, median hs-CRP concentration 2.4\u2005mg\/L (inter-quartile range 1.1\u20135.1). After median follow-up of 5 years, 171 patients had a MACE and 207 had HHF. After controlling for potential confounders, a two-fold increase in hs-CRP was associated with a 12% (95% CI 0\u201326) higher cause-specific hazard of MACE and a 26% (95% CI 13\u201340) higher cause-specific hazard of HHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag538","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:25:47Z","timestamp":1792409147000},"source":"Crossref","is-referenced-by-count":0,"title":["Low-grade inflammation and cardiovascular events among patients with chronic kidney disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-528X","authenticated-orcid":false,"given":"Justina","family":"Motiejunaite","sequence":"first","affiliation":[{"name":"Service de Physiologie et Explorations Fonctionnelles, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Bichat-Claude Bernard , Paris 75018 ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris 75006 ,","place":["France"]},{"name":"Centre for Research in Epidemiology and Population Health (CESP), Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Clinical Epidemiology and Pharmaco-Epidemiology Team , Villejuif 94800 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00efla","family":"Benamara","sequence":"additional","affiliation":[{"name":"Medical Affairs, Novo Nordisk France , Puteaux 92800 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6329-9339","authenticated-orcid":false,"given":"Emilie","family":"Moutard","sequence":"additional","affiliation":[{"name":"Centre for Research in Epidemiology and Population Health (CESP), Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Clinical Epidemiology and Pharmaco-Epidemiology Team , Villejuif 94800 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie-Hypertension, Dialyse, Transplantation R\u00e9nale, CHU de Tours , Tours 37000 ,","place":["France"]},{"name":"INSERM UMR1327, ISCHEMIA, Universit\u00e9 de Tours , Tours 37000 ,","place":["France"]},{"name":"l'Institut Lorrain du Coeur et des Vaisseaux - CHRU de Nancy, 54500 Vandoeuvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-6487","authenticated-orcid":false,"given":"Natalia","family":"Alencar de Pinho","sequence":"additional","affiliation":[{"name":"Centre for Research in Epidemiology and Population Health (CESP), Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Clinical Epidemiology and Pharmaco-Epidemiology Team , Villejuif 94800 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Saint Joseph , Paris 75014 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-9818","authenticated-orcid":false,"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, 2 , Martin-Luther-King Avenue, Limoges 87042 ,","place":["France"]},{"name":"INSERM U1094 & IRD, Limoges University , Limoges 87025 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5771-5996","authenticated-orcid":false,"given":"Ziad A","family":"Massy","sequence":"additional","affiliation":[{"name":"Centre for Research in Epidemiology and Population Health (CESP), Inserm U1018, Paris-Saclay University, Versailles Saint-Quentin University, Clinical Epidemiology and Pharmaco-Epidemiology Team , Villejuif 94800 ,","place":["France"]},{"name":"Nephrology Department, Ambroise Par\u00e9 University Hospital , Boulogne-Billancourt, Paris 92100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026103013015064000_zwag538-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026103013015064000_zwag538-B2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - A systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"2026103013015064000_zwag538-B3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40620-023-01626-8","article-title":"Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney Study","volume":"36","author":"Filipa Alexandre","year":"2023","journal-title":"J Nephrol"},{"key":"2026103013015064000_zwag538-B4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026103013015064000_zwag538-B5","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026103013015064000_zwag538-B6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026103013015064000_zwag538-B7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026103013015064000_zwag538-B8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjpc\/zwaf779","article-title":"The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis","volume":"33","author":"Agboola","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"2026103013015064000_zwag538-B9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","article-title":"Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"2026103013015064000_zwag538-B10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026103013015064000_zwag538-B11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/eurheartj\/ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the \u2018SMuRF-less but inflamed\u2019","volume":"47","author":"Ridker","year":"2026","journal-title":"Eur Heart J"},{"key":"2026103013015064000_zwag538-B12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2026103013015064000_zwag538-B13","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14040280","article-title":"Uremic toxins and cardiovascular risk in chronic kidney disease: what have we learned recently beyond the past findings?","volume":"14","author":"El Chamieh","year":"2022","journal-title":"Toxins (Basel)"},{"key":"2026103013015064000_zwag538-B14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/eurheartj\/ehad115","article-title":"Proteomic cardiovascular risk assessment in chronic kidney disease","volume":"44","author":"Deo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026103013015064000_zwag538-B15","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"2026103013015064000_zwag538-B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jjcc.2023.05.002","article-title":"Prognostic value of high-sensitivity C-reactive protein among chronic kidney disease patients undergoing percutaneous coronary intervention","volume":"82","author":"Jones","year":"2023","journal-title":"J Cardiol"},{"key":"2026103013015064000_zwag538-B17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int"},{"key":"2026103013015064000_zwag538-B18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/ndt\/gft388","article-title":"The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study","volume":"29","author":"Stengel","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026103013015064000_zwag538-B19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ndt\/gfy058","article-title":"Risk profile, quality of life and care of patients with moderate and advanced CKD: the French CKD-REIN cohort study","volume":"34","author":"Stengel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026103013015064000_zwag538-B20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026103013015064000_zwag538-B21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026103013015064000_zwag538-B22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"2026103013015064000_zwag538-B23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2024.04.013","article-title":"Sex and the risk of atheromatous and nonatheromatous cardiovascular disease in CKD: findings from the CKD-REIN cohort study","volume":"84","author":"Faucon","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026103013015064000_zwag538-B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052775","article-title":"Association of hsCRP, white blood cell count and ferritin with renal outcome in chronic kidney disease patients","volume":"7","author":"Tsai","year":"2012","journal-title":"PLoS One"},{"key":"2026103013015064000_zwag538-B25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.5551\/jat.33530","article-title":"Serum albumin and high-sensitivity C-reactive protein are independent risk factors of chronic kidney disease in middle-aged Japanese individuals: the circulatory risk in communities study","volume":"23","author":"Kubo","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"2026103013015064000_zwag538-B26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/eurjpc\/zwaf609","article-title":"Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the US and the UK","volume":"33","author":"Ray","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026103013015064000_zwag538-B27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2013-203293","article-title":"Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions","volume":"73","author":"Johnsson","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026103013015064000_zwag538-B28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.amjcard.2003.11.018","article-title":"Association of ferritin and lipids with C-reactive protein","volume":"93","author":"Mainous","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026103013015064000_zwag538-B29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011728","article-title":"Transferrin saturation, Serum iron, and ferritin in heart failure: prognostic significance and proteomic associations","volume":"18","author":"Gan","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026103013015064000_zwag538-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07853890.2017.1325967","article-title":"Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults","volume":"50","author":"Mazidi","year":"2018","journal-title":"Ann Med"},{"key":"2026103013015064000_zwag538-B31","article-title":"ESKD, Major cardiovascular events, and death associated with systemic inflammation","volume":"11","author":"Halimi","year":"2026","journal-title":"Kidney Int Rep"},{"key":"2026103013015064000_zwag538-B32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017980","article-title":"Low high-sensitivity C-reactive protein level in Korean patients with chronic kidney disease and its predictive significance for cardiovascular events, mortality, and adverse kidney outcomes: results from KNOW-CKD","volume":"9","author":"Lee","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026103013015064000_zwag538-B33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.kint.2017.09.011","article-title":"Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation","volume":"93","author":"Storey","year":"2018","journal-title":"Kidney Int"},{"key":"2026103013015064000_zwag538-B34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12986-025-00982-5","article-title":"Remnant cholesterol, high-sensitivity C-reactive protein, and risk of incident coronary heart disease among patients with chronic kidney disease based on UK biobank","volume":"22","author":"Han","year":"2025","journal-title":"Nutr Metab (Lond)"},{"key":"2026103013015064000_zwag538-B35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.5551\/jat.64047","article-title":"Impact of C-reactive protein on long-term cardiac events in stable coronary artery disease patients with chronic kidney disease","volume":"30","author":"Tokuda","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"2026103013015064000_zwag538-B36","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005336","article-title":"Risk factors for heart failure in patients with chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study","volume":"6","author":"He","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026103013015064000_zwag538-B37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","article-title":"C-reactive protein and risk of incident heart failure in patients with cardiovascular disease","volume":"82","author":"Burger","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026103013015064000_zwag538-B38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2018.02.027","article-title":"The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after &gt;10 years of follow-up: the multi-ethnic study of atherosclerosis (MESA)","volume":"264","author":"Cainzos-Achirica","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026103013015064000_zwag538-B39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026103013015064000_zwag538-B40","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","article-title":"Renal-cardiac crosstalk in the pathogenesis and progression of heart failure","volume":"136","author":"Noels","year":"2025","journal-title":"Circ Res"},{"key":"2026103013015064000_zwag538-B41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026103013015064000_zwag538-B42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(25)01393-5","article-title":"Prioritising the primary prevention of heart failure","volume":"406","author":"Khan","year":"2025","journal-title":"Lancet"},{"key":"2026103013015064000_zwag538-B43","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026103013015064000_zwag538-B44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol"},{"key":"2026103013015064000_zwag538-B45","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"key":"2026103013015064000_zwag538-B46","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2215\/CJN.10441015","article-title":"Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD","volume":"11","author":"Sun","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026103013015064000_zwag538-B47","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1002\/iid3.818","article-title":"Interleukin-6 levels can be used to estimate cardiovascular and all-cause mortality risk in dialysis patients: a meta-analysis and a systematic review","volume":"11","author":"Chen","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"2026103013015064000_zwag538-B48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2026103013015064000_zwag538-B49","author":"Novo Nordisk"},{"key":"2026103013015064000_zwag538-B50","author":"Bhatt"},{"key":"2026103013015064000_zwag538-B51","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology","volume":"87","author":"Mensah","year":"2026","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag538\/72259311\/zwag538.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag538\/72259311\/zwag538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:02:06Z","timestamp":1793379726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag538\/8965433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag538","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"article-number":"zwag538"}}